| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF2C2 |
| Uniprot No | Q9UKV8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 517-818aa |
| 氨基酸序列 | LVVVILPGKTPVYAEVKRVGDTVLGMATQCVQMKNVQRTTPQTLSNLCLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRFKPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDELQILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLV |
| 分子量 | 36.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EIF2C2(Argonaute 2. AGO2)蛋白的3篇参考文献示例：
1. **"Structural insights into the human Argonaute2 protein in RNA interference"**
- **作者**：Li et al.
- **摘要**：通过X射线晶体学解析重组人AGO2蛋白的结构，揭示了其与siRNA复合物的结合模式，阐明了其在RNA诱导的基因沉默中的构象变化机制。
2. **"Functional characterization of recombinant human EIF2C2 in miRNA-mediated gene regulation"**
- **作者**：Smith & Johnson
- **摘要**：利用体外重组表达系统研究AGO2蛋白在miRNA通路中的作用，证实其通过结合miRNA调控靶mRNA的翻译抑制和降解。
3. **"AGO2-mediated RNA interference in cancer cell models: Implications for therapeutic targeting"**
- **作者**：Wang et al.
- **摘要**：通过重组AGO2蛋白递送靶向致癌基因的siRNA，验证其增强癌细胞凋亡的效果，为基于RNAi的抗肿瘤治疗提供实验依据。
(注：上述文献为示例性概括，实际引用需依据具体研究内容查阅真实发表的论文。)
**Background of Recombinant Human EIF2C2 Protein**
Recombinant human EIF2C2. also known as Argonaute-2 (AGO2), is a key protein involved in RNA-mediated gene silencing pathways. As a core component of the RNA-induced silencing complex (RISC), EIF2C2 plays a critical role in microRNA (miRNA) and small interfering RNA (siRNA) function, regulating gene expression by binding to target mRNAs and either degrading them or inhibiting translation. Its structure includes conserved PAZ and PIWI domains, with the PIWI domain conferring endonuclease activity essential for mRNA cleavage.
Produced through recombinant DNA technology, the protein is expressed in heterologous systems (e.g., *E. coli*, mammalian cells) to ensure high purity and functionality for research applications. This engineered approach enables scalable production and minimizes batch variability.
EIF2C2 is vital for studying post-transcriptional gene regulation, cellular differentiation, and apoptosis. Its dysfunction is linked to cancers, viral infections, and neurological disorders, making it a target for therapeutic development, including RNA-based therapies and CRISPR-Cas9 systems. Recombinant EIF2C2 also facilitates *in vitro* studies of RISC assembly, miRNA-mRNA interactions, and high-throughput drug screening. By offering a well-characterized, active form of the protein, it accelerates mechanistic insights into gene silencing and supports advancements in precision medicine.
×
